Prelude Therapeutics Incorporated (PRLD) Earnings Call Transcripts

Prelude Therapeutics Incorporated's Latest Earnings Call - June 10, 2026

In the earnings call held on June 10, 2026, Prelude Therapeutics highlighted significant advancements in their oncology pipeline, particularly focusing on their CAT-6 program for ER-positive breast cancer. Management emphasized the potential of their selective degrader approach to mitigate toxicities associated with existing therapies, signaling a strong commitment to improving patient outcomes. While specific revenue figures were not disclosed, the company maintained a positive outlook on their clinical development timeline, with expectations for initial clinical data by the second half of 2027.

Reported metrics

Guidance from management

Management maintained a positive outlook, indicating that they expect to generate initial clinical proof of concept by the second half of 2027, with a focus on safety and efficacy differentiation.

What management said

Yes. Again, I think on the early clinical data suggests that there is activity across a broad range of ER-positive breast cancer is independent of PIK3CA mutation or ESR1 status and especially in combination with fulvestrant, I think Pfizer is showing really compelling data that led them to initiate a Phase III study. As I mentioned, there are some toxicities associated with the approach. Pfizer has taken an approa...

There's preclinical data, again, that supports -- if you knock out both CAP6A and Cat6b that the bone marrow toxicity is much more severe. It has an impact on the hematopoietic stem cells. Whereas if you knock out either one as a single knockout that, that toxicity is mitigated, there's almost no impact. So it's really our thinking because you need to knock down Cat6a for the tumor biology. Sparing Cat 6 should the...

What analysts pressed on

Analysts expressed concerns regarding the competitive landscape and the ability to differentiate Prelude's therapies from existing options. There were also questions about the timeline for clinical data and the potential for unforeseen toxicities.

Main topics on the call

• CAT-6 Program Development — Prelude is advancing its CAT-6 program, which targets CAT 6A in ER-positive breast cancer. Management stated, "we think we can more completely impact the Cat 6A biology, the tumor biology and spare some of the bone marro...
• Preclinical Data Highlights — The preclinical data presented at AACR showcased the monotherapy activity of PRT13722, with "complete regressions in multiple models in all of the animals," suggesting strong efficacy compared to existing therapies.
• Market Opportunity in ER-positive Breast Cancer — Management noted that the ER-positive breast cancer market represents a "$5 billion plus opportunity potentially," highlighting the significant commercial potential if their therapies demonstrate clinical success.
• IND Submission Timeline — Management guided that they expect to be in a position to start understanding the profile of their molecule by the second half of 2027, with safety data anticipated to emerge quickly.

Read the full Prelude Therapeutics Incorporated transcript (June 10, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 16 Prelude Therapeutics Incorporated earnings call transcripts on record, spanning March 10, 2021 to June 10, 2026. Based on this history, Prelude Therapeutics Incorporated reports semi-annually. The most recent call on file is dated June 10, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

PRLD

Exchange

NasdaqGS

Country

US

Sector

Health Care

Industry

Biotechnology

Calls on record

16

First call

March 10, 2021

Most recent

June 10, 2026

Reporting cadence

semi-annually